An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment
Clinical Pharmacology & Therapeutics · 2025-02 · 117 (2) · 337-342
DOI: 10.1002/cpt.3463 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 22.10.2024. Verfasst von Ashish Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA. Hauptthemen laut MEDLINE: Drug Industry, Renal Insufficiency, Drug Development, Kidney. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The IQ CPLG Organ Impairment WG conducted a survey to understand how various IQ member companies develop dosing recommendations for patients with renal impairment. Eighteen IQ member companies participated in the survey. The survey results were summarized by the working group in light of the regulatory renal impairment guidance documents as well as recent publications from the pharmaceutical industry and nephrology community. There were two important learnings from the survey: (i) pharmaceutical companies do not use a consistent methodology to assess renal function in their drug development programs. (ii) there has been significant improvement in predicting how kidney function affects drug pharmacokinetics (PK) and thus dose recommendations. Applying model‐based methods such as population PK, physiologically‐based PK (PBPK), and virtual controls has enabled earlier prediction of how kidney function influences PK, leading to the participation of more patients with impaired kidney function in Phase 2 and 3 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
- Merck and Co., LLC, Rahway, New Jersey, USA.
- Xencor Inc, Pasadena, California, USA.
- Pfizer, Inc., Groton, Connecticut, USA.
ORCID-Profile: Ashish Sharma, Islam R Younis, Jitendra Kanodia, Vaishali Sahasrabudhe
Zitieren
APA
Sharma, A., Younis, I. R., Kanodia, J., & Sahasrabudhe, V. (2025). An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment. Clinical Pharmacology & Therapeutics, 117(2), 337-342. https://doi.org/10.1002/cpt.3463
Vancouver
Sharma A, Younis IR, Kanodia J, Sahasrabudhe V. An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment. Clinical Pharmacology & Therapeutics. 2025;117(2):337-342. doi:10.1002/cpt.3463
BibTeX
@article{Sharma2025,
author = {Sharma, Ashish and Younis, Islam R and Kanodia, Jitendra and Sahasrabudhe, Vaishali},
title = {An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {2},
pages = {337--342},
doi = {10.1002/cpt.3463}
}
EUVIMED